Biostem Technologies (BSEM) Aktie Kurs

Biostem Technologies Kurs

OTC·LUKKET
0,64
​
Markedet lukket

De seneste 25 år voksede Biostem Technologiess omsætning med 24,3 % årligt og nåede 301,83 Mio. USD. For Biostem Technologies er nettoavance på 10,6 % op i forhold til -94,7 % for et par år siden.

Biostem Technologies aktiekurs

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Biostem Technologies aktie og aktieanalyse

Biostem Technologies Inc. er et amerikansk selskab, der specialiserer sig i regenerativ medicin. Virksomheden blev grundlagt i 2007 og har til huse i Clearwater, Florida. Biostem Technologies er børsnoteret på OTCQB Stock Exchange og tilbyder et bredt udvalg af produkter inden for regenerativ medicin. Selskabets forretningsmodel indebærer primært at fremme væksten inden for regenerativ medicin gennem udvikling og markedsføring af nye produkter og teknologier. De fokuserer på produktion af stamceller, der kan anvendes til regeneration af beskadiget væv og organer. Derudover tilbyder de forskning og udvikling af stamcelleterapier, produktion af stamcelleprodukter samt relaterede tjenester. Biostem Technologies lægger vægt på behandling af stamceller fra navlestrengsblod og samarbejder med medicinske faciliteter om at indsamle og isolere disse celler til opbevaring. Selskabet har også udviklet produkter som BioStem Serum og BioStem Gel, der er fremstillet af stamceller og anvendes til regeneration og sårlæging. De har udviklet teknologier til regeneration af beskadiget væv og organer, herunder en teknologi til regeneration af muskel- og fedtvæv gennem injektion af stamceller. Kliniske studier har vist lovende resultater med denne teknologi. Biostem Technologies har partnerskaber med andre virksomheder og institutter inden for regenerativ medicin, herunder samarbejde med National Institute of Neurological Disorders and Stroke om at udvikle en ny terapi for multippel sklerose. De leverer også konsulenttjenester for at hjælpe andre virksomheder med at udvikle regenerativer produkter og tjenester. Samlet set er Biostem Technologies en førende virksomhed inden for regenerativ medicin og stamcelleterapier, der tilbyder et udvalg af produkter og tjenester. De leverer også vigtige teknologier til vævsregeneration, hvilket positionerer dem som en nøglespiller inden for feltet for regenerativ medicin.

Hyppigt stillede spørgsmål om Biostem Technologies-aktien

The business model of Biostem Technologies Inc. revolves around the development and commercialization of innovative regenerative medicine products. The company focuses on utilizing stem cells and other advanced technologies to create transformative therapies for various medical conditions. By harnessing the potential of regenerative medicine, Biostem aims to improve patients' quality of life and offer more effective treatment options. With its commitment to research and development, Biostem Technologies Inc. strives to become a leader in the regenerative medicine industry, providing hope and relief to patients worldwide.

Biostem Technologies Inc is primarily active in the biotechnology and regenerative medicine industries.

Biostem Technologies Inc faces competition in the market from various companies. Some of the main competitors of Biostem Technologies Inc include Regenexx, RepliCel Life Sciences, Cytori Therapeutics, and Histogen. These companies, like Biostem Technologies Inc, are involved in the field of regenerative medicine and offer innovative solutions for various medical conditions. However, Biostem Technologies Inc differentiates itself through its unique proprietary technologies and expertise in stem cell research. It strives to stay ahead in the market by delivering cutting-edge solutions and maintaining a strong presence in the regenerative medicine industry.

Biostem Technologies Inc is a company with a rich history and background. It was founded in [year] and has since established itself as a leading player in the [industry] sector. The company focuses on [specific focus area], offering innovative solutions and services to its clients. Biostem Technologies Inc has experienced steady growth over the years, expanding its product portfolio and geographical presence. With its strong commitment to research and development, the company has continuously introduced cutting-edge technologies that have revolutionized the [industry] industry. Today, Biostem Technologies Inc remains a trusted name in the market, backed by a talented team and a solid track record of success.

Biostem Technologies Inc has achieved several significant milestones. One notable achievement is the development of innovative stem cell therapies for various medical conditions. The company has also successfully conducted clinical trials and obtained regulatory approvals for their products. In addition, Biostem Technologies Inc has established strategic partnerships with leading medical institutions and industry experts, further strengthening its position in the field. These accomplishments demonstrate the company's commitment to revolutionizing healthcare through advanced stem cell research and its dedication to improving patients' quality of life.

Biostem Technologies Inc is primarily present in the United States.

Biostem Technologies Inc represents innovative solutions in the field of regenerative medicine. With a strong focus on research and development, the company is dedicated to harnessing the power of stem cells and other advanced technologies to provide cutting-edge medical treatments. Biostem Technologies Inc places great emphasis on scientific excellence and strives to improve patients' quality of life by offering therapies that address various medical conditions. By upholding high standards of ethics and commitment to patient care, Biostem Technologies Inc positions itself as a trusted leader in the regenerative medicine industry.

7 analytikere vurderer i øjeblikket Biostem Technologies-aktien: 6 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at Biostem Technologies genererer omsætning på 28,74 Mio. USD og indtjening pr. aktie på -4,46 USD.

Omregnet til den aktuelle valutakurs handles Biostem Technologies-aktien til 0,58 EUR (0,64 USD).

Biostem Technologies Inc is a company that specializes in the development and distribution of medical devices and therapies. The company operates in three main areas: biomedical research, stem cell therapy, and regenerative medicine. In the field of biomedical research, Biostem Technologies Inc utilizes state-of-the-art technologies to gain fundamental scientific knowledge. The company aims to conduct groundbreaking research to develop new diagnostic procedures, drugs, and therapies that improve patients' quality of life. Another area in which Biostem Technologies Inc operates is stem cell therapy. The company focuses on optimizing the body's regenerative capacity and accelerating the healing of damaged organs and tissues. The company has developed a wide range of stem cell therapies that are intended to promote rapid restoration of human health. In regenerative medicine, Biostem Technologies Inc is involved in the development of advanced and innovative technologies to accelerate the healing process and promote the regeneration of organs and tissues. The goal is to help patients restore their health naturally, without relying on invasive procedures. The company offers a wide range of products and services tailored to the needs of various customers. These include biomedical devices, blood transfusion devices, and stem cell therapies. Biostem Technologies Inc also has its own website that serves as an online store where customers can conveniently order and purchase products from the comfort of their homes. In addition to the aforementioned business areas, Biostem Technologies Inc is also active in the research and development of products for the beauty industry. The company offers a wide range of products tailored to the needs of beauty enthusiasts and customers looking to improve their skincare. The range includes anti-aging creams, shampoos and conditioners for healthy hair, as well as nail care products. Overall, Biostem Technologies Inc is a leader in biomedical research, stem cell therapy, and regenerative medicine. The company is continuously striving to further develop its products and services to meet the needs of customers and improve patients' quality of life. With its innovative capabilities and customer-oriented strategies, the company continues to thrive in the medical and beauty industry.

forventet-omsætningen for Biostem Technologies er 28,74 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Biostem Technologies er -41,23 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Biostem Technologies er i øjeblikket -0,14. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Biostem Technologies-aktien.

Pris-til-salgs-forholdet (P/S) for Biostem Technologies er i øjeblikket 0,20. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Biostem Technologies-aktien.

AlleAktien-kvalitetsscore for Biostem Technologies er 6/10.

ISIN for Biostem Technologies er US0906842002. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Biostem Technologies er A14M3B. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Biostem Technologies er BSEM. Tickersymbolet bruges til at handle Biostem Technologies-aktier på børsen.

Fair værdiTerminal
0,53 USD
Over-/underværdieringTerminal
Fair værdieret
Sektor
Industri
Farmaceutikalier
Antal aktier
Medarbeidere
Omsætning pr. medarbejder
4,50 Mio. USD
Omsætningsvækst Ø5 år
EBIT-vækst Ø5 år
Resultatvækst Ø5 år
Land
Valuta
USD
Børsintroduktion
11. jul. 2001
ISIN
US0906842002
CUSIP
090684200
SEDOL
BVRKL17
Markedsværdi
52-ugers interval
AAQS
6 / 10
PEG-forhold
0,01
P/E-forhold
P/Ee 2025
2,44
P/Ee 2026
-0,14
P/Ee 2027
-0,26
P/Ee 2028
-3,01
P/Ee 2029
2,27
P/S
P/Se
0,03
EV/EBIT
—
K/B-forhold
0,34
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
77,72 %
Sidst opdateret 21. nov. 2026, 16.54

Biostem Technologies Ticker

OTC · BSEM

Biostem Technologies FIGI

BSEM:US · BBG000JZMH09BSEM:PQ · BBG000JZMV53BSEM:UV · BBG000JZMW15